Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.35 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330890 | 0.88 | ALDH1A1 (0.34) | KMT2AKDM4EALDH1A1CYP2D6MAPK8 | |
| SCHEMBL14330869 | 0.88 | ALDH1A1 (0.37) | KMT2AKDM4EALDH1A1CYP2D6MAPK8 | |
| SCHEMBL14206542 | 0.86 | KDM4E (0.38) | KMT2AKDM4EALDH1A1CYP2D6MAPK8 | |
| SCHEMBL14207041 | 0.81 | ALDH1A1 (0.40) | KMT2AKDM4EALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL13322705 | 0.79 | ALDH1A1 (0.42) | KMT2AKDM4EALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL11888022 | 0.75 | MAPK1 (0.41) | KMT2AKDM4EALDH1A1CYP2D6GAA | |
| SCHEMBL14328397 | 0.75 | THRB (0.40) | KMT2AKDM4EALDH1A1CYP2D6L3MBTL1 | |
| SCHEMBL14328407 | 0.74 | KDM4E (0.36) | KMT2AKDM4EALDH1A1CYP2D6 | |
| SCHEMBL10151195 | 0.73 | KDM4E (0.38) | KMT2AKDM4EALDH1A1CYP2D6 | |
| SCHEMBL14206459 | 0.73 | CHEK1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078003-B1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9206142-B2 | Anilinopiperazine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206142-B2 | Anilinopiperazine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120328691-A1 | ANILINOPIPERAZINE DERIVATIVES AND METHODS OF USE THEREOF | MAPK15, CDK15, MAPKAPK5 | KMT2A 3820/4885KDM4E 3595/4885ALDH1A1 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.